RNA and DNA incorporation sites (N/A)

RNA and DNA incorporation sites refer to the specific positions within a growing nucleic acid chain where nucleotides are added during the processes of replication and transcription (NIH, 2023). In a pharmacological context, these sites serve as the functional target for a broad class of drugs known as antimetabolites and nucleoside/nucleotide analogs (PubChem, 2024). These therapeutic agents are designed to mimic natural nucleosides, tricking DNA or RNA polymerases into incorporating them into the genetic material of rapidly dividing cancer cells or replicating viruses (StatPearls, 2023). Once integrated, these analogs disrupt further synthesis by causing immediate chain termination or by creating bulky adducts that interfere with the binding of essential replication proteins (Nature Reviews Cancer, 2017). This disruption activates robust DNA damage signaling pathways, such as the p53-mediated response, which ultimately induces apoptosis in malignant cells (PubMed, 2021). Because these drugs rely on the high rate of nucleic acid synthesis in target cells, they are highly effective in treating various leukemias, solid tumors, and viral infections like HIV and Herpes (NIH, 2023).

Other names

DNA incorporationRNA incorporationNucleic acid synthesis sitesNucleotide analog incorporation sites

Nucleoside and nucleotide analogs serve as fraudulent substrates that are incorporated into nascent DNA or RNA strands by cellular or viral polymerases, leading to chain termination, structural instability, or lethal mutagenesis (StatPearls, 2023; Nature Reviews Cancer, 2017).